B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells] for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
City of Hope Medical Center, Duarte, CA
Relapsed or Refractory Mantle Cell Lymphoma (MCL)+2 More
BAFFR-CAR T cells - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Eligible Conditions

  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: From CAR T cell infusion to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed up to 15 years.

Year 15
Progression-free survival (PFS)
Year 15
Overall Survival (OS)
Year 1
B Cell Quantification
Disease Response
Incidence of adverse events
Maximum Tolerated Dose (MTD)
Minimal Residual Disease (MRD)

Trial Safety

Safety Progress

1 of 3

Other trials for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Trial Design

1 Treatment Group

B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T...
1 of 1
Experimental Treatment

18 Total Participants · 1 Treatment Group

Primary Treatment: B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells] · No Placebo Group · Phase 1

B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells]
Biological
Experimental Group · 1 Intervention: BAFFR-CAR T cells · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from car t cell infusion to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed up to 15 years.
Closest Location: City of Hope Medical Center · Duarte, CA
Photo of Duarte  1Photo of Duarte  2Photo of Duarte  3
2002First Recorded Clinical Trial
1 TrialsResearching Relapsed or Refractory Mantle Cell Lymphoma (MCL)
142 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects with other relapsed or refractory BAFFR+ B cell lymphoma with no standard of care options are allowed during initial dose escalation phase, not the dose expansion phase.
The study is a clinical trial and the study subjects will be provided with archival tissue from diagnostic tumor biopsies.
You have histologically confirmed Mantle Cell Lymphoma.
You have had at least 1 prior regimen of therapy for relapsed/refractory disease.
The disease must be measurable by CT scan (≥1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.